Accredited Investor; Access to Information. Holder represents and warrants that as of the date hereof Holder is an accredited investor within the meaning of Rule 501 of Regulation D promulgated under the Act. Holder has had the opportunity to ask questions of, and to receive answers from, appropriate executive officers of the Company with respect to the terms and conditions of the transactions contemplated hereby and with respect to the business, affairs, financial condition and results of operations of the Company. Holder has had access to such financial and other information as is necessary in order for Holder to make a fully informed decision as to investment in the Company, and has had the opportunity to obtain any additional information necessary to verify any of such information to which Holder has had access.
Accredited Investor; Access to Information. Novartis is an “accredited investor” as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to investments in shares presenting an investment decision like that involved in the purchase of the Shares. Novartis has been furnished with materials relating to the offer and sale of the Shares, that have been requested by Novartis, including, without limitation, Ionis’s SEC Documents, and Novartis has had the opportunity to review the SEC Documents. Novartis has been afforded the opportunity to ask Ionis and Akcea questions. Neither such inquiries nor any other investigation conducted by or on behalf of Novartis or its representatives or counsel will modify, amend or affect Novartis’ right to rely on the truth, accuracy and completeness of the SEC Documents and Ionis’s and Akcea’s representations and warranties contained in this Agreement.
Accredited Investor; Access to Information. Purchaser is an “accredited investor” as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to investments in shares presenting an investment decision like that involved in the purchase of the Shares. Purchaser has been furnished with materials relating to the offer and sale of the Shares that have been requested by Purchaser, including the SEC Documents, and Purchaser has had the opportunity to review the SEC Documents. Purchaser has been afforded the opportunity to ask questions of the Company. Neither such inquiries nor any other investigation conducted by or on behalf of Purchaser or its representatives or counsel will modify, amend or affect Purchaser’s right to rely on the truth, accuracy and completeness of the SEC Documents and the Company’s representations and warranties contained in this Agreement.
Accredited Investor; Access to Information. Biogen is an “accredited investor” as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to investments in shares presenting an investment decision like that involved in the purchase of the Shares. Biogen has been furnished with materials relating to the offer and sale of the Shares, that have been requested by Biogen, including, without limitation, Sangamo’s SEC Documents, and Biogen has had the opportunity to review the SEC Documents. Biogen has been afforded the opportunity to ask questions of Sangamo. Neither such inquiries nor any other investigation conducted by or on behalf of Biogen or its representatives or counsel will modify, amend or affect Biogen's right to rely on the truth, accuracy and completeness of the SEC Documents and Sangamo’s representations 80254187_15 and warranties contained in this Agreement. Biogen has, with respect to all matters relating to this Agreement and the offer and sale of the Shares, not relied upon counsel.
Accredited Investor; Access to Information. Kissei is an “accredited investor” as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to investments in shares presenting an investment decision like that involved in the purchase of the Shares. Kissei has been furnished with materials relating to the offer and sale of the Shares that have been requested by Kissei, including, without limitation, the SEC Documents, and Kissei has had the opportunity to review the SEC Documents. Kissei also has access to non-public information relating to the MN-221 Program, including information as the licensor under the License Agreement and Kissei has been afforded an opportunity to ask questions of MediciNova. Kissei has, in connection with Kissei’s decision to purchase the Shares, not relied upon any representations or other information (whether oral or written) other than as set forth in the representations and warranties of MediciNova contained herein, and Kissei has, with respect to all matters relating to this Agreement and the offer and sale of the Shares, relied solely upon the advice of Kissei’s own counsel and has not relied upon counsel to MediciNova.
Accredited Investor; Access to Information. Such Securityholder and, to the knowledge of such Securityholder, each limited partner of such Securityholder in the case of a Securityholder which is a limited partnership, and each partner of such Securityholder in the case of a Securityholder which is a general partnership, is an "accredited investor," as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act. Such Securityholder, the shareholders of the general partner of such Securityholder, if any, and each of the limited partners of such Securityholder, if any, has had substantial experience in private securities transactions like this one, is capable of evaluating the merits and risks of an investment in the Company, and has had a full opportunity to discuss the business, management, and financial affairs of the Company with the Company's management. Such Securityholder has received all requested documents from the Company and has had a full opportunity to ask questions of, and receive answers from, the officers of the Company.
Accredited Investor; Access to Information. Chiesi is an “accredited investor” as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to investments in shares presenting an investment decision like that involved in the purchase of the Inhibrx Common Shares. Chiesi has been afforded the opportunity to ask Inhibrx questions, and receive answers from, the officers of Inhibrx concerning this Agreement, the exhibits and schedules attached hereto and the transactions contemplated hereby, as well as Inhibrx’s business, management and financial affairs, which questions were answered to its satisfaction. Chiesi understands that such discussions, as well as any information issued by Inhibrx, were intended to describe certain aspects of Inhibrx’s business and prospects, but were not necessarily a thorough or exhaustive description. Chiesi acknowledges that any business plans prepared by Inhibrx have been, and continue to be, subject to change and that any projections included in such business plans or otherwise are necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the projections will not materialize or will vary significantly from actual results. Neither such inquiries nor any other investigation conducted by or on behalf of Chiesi or its representatives or counsel will modify, amend or affect Chiesi’s right to rely on the truth, accuracy and completeness of Inhibrx’s representations and warranties contained in this Agreement.
Accredited Investor; Access to Information. The Holder is an “accredited investor” as defined in Regulation D under the Securities Act, and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to investments in shares presenting an investment decision like that involved in the purchase of the Shares. The Holder has been furnished with materials relating to the offer and sale of the Shares that have been requested by the Holder, including all reports, schedules, forms, statements and other documents (including exhibits and all other information incorporated therein), and any required amendments to any of the foregoing, filed with the U.S. Securities and Exchange Commission in accordance with the Securities Act and the Exchange Act, and the Holder has been afforded the opportunity to ask questions of the Company.
Accredited Investor; Access to Information. Zentalis is an “accredited investor” as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to investments in shares presenting an investment decision like that involved in the acquisition of the Shares. Zentalis has been furnished with, or otherwise had access to, materials relating to the offer and sale of the Shares, that have been requested by Zentalis, including, without limitation, Immunome’s public filings made available on the SEC’s electronic data gathering and retrieval system (EXXXX) as of the date hereof (the “SEC Documents”), and Zentalis has had the opportunity to review such materials. Zentalis has been afforded the opportunity to ask questions of Immunome. Neither such inquiries nor any other investigation conducted by or on behalf of Zentalis or its representatives or counsel will modify, amend or affect Zentalis’s right to rely on the truth, accuracy and completeness of the SEC Documents and Immunome’s representations and warranties contained in this Agreement.
Accredited Investor; Access to Information. Lilly is an “accredited investor” as defined in Regulation D under the Securities Act and is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to, investments in shares presenting an investment decision like that involved in the purchase of the Shares. Lilly has been furnished with materials relating to the offer and sale of the Shares, that have been requested by Lilly, including, without limitation, the SEC Documents, and Lilly has had the opportunity to review the SEC Documents. Lilly has been afforded the opportunity to ask questions of
